Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension

M J Cork, D Thaçi, L F Eichenfield, P D Arkwright, T Hultsch, J D Davis, Y Zhang, X Zhu, Z Chen, M Li, M Ardeleanu, A Teper, B Akinlade, A Gadkari, L Eckert, M A Kamal, M Ruddy, N M H Graham, G Pirozzi, N Stahl, A T DiCioccio, A Bansal, M J Cork, D Thaçi, L F Eichenfield, P D Arkwright, T Hultsch, J D Davis, Y Zhang, X Zhu, Z Chen, M Li, M Ardeleanu, A Teper, B Akinlade, A Gadkari, L Eckert, M A Kamal, M Ruddy, N M H Graham, G Pirozzi, N Stahl, A T DiCioccio, A Bansal

Abstract

Background: Dupilumab (monoclonal antibody inhibiting IL-4/IL-13 signalling) is approved for use in adolescents aged ≥ 12 years with inadequately controlled moderate-to-severe atopic dermatitis (AD). Dupilumab significantly improved AD signs/symptoms in a 16-week, randomised, placebo-controlled phase III trial in adolescents (NCT03054428).

Objectives: To characterize the pharmacokinetics of dupilumab, and long-term safety and efficacy in adolescents.

Methods: This was a global, multicentre, phase IIa, open-label, ascending-dose, sequential cohort study with a phase III open-label extension (OLE) in adolescents with moderate-to-severe AD. In the phase IIa study, patients received one dupilumab dose (2 mg kg-1 or 4 mg kg-1 ) and 8 weeks of pharmacokinetic sampling. Thereafter, patients received the same dose weekly for 4 weeks, with 8-week safety follow-up. Patients then enrolled in the OLE, continuing 2 mg kg-1 or 4 mg kg-1 dupilumab weekly. Primary end points were dupilumab concentration-time profile and incidence of treatment-emergent adverse events (TEAEs). Secondary outcomes included Eczema Area and Severity Index (EASI).

Results: Forty adolescents received dupilumab in the phase IIa study; 36 enrolled in the OLE. Dupilumab showed nonlinear, target-mediated pharmacokinetics. Mean ± SD trough dupilumab concentrations in serum at week 48 (OLE) were 74 ± 19 mg L-1 and 161 ± 60 mg L-1 for 2 mg kg-1 and 4 mg kg-1 , respectively. Dupilumab was well tolerated over 52 weeks; the most common TEAEs were nasopharyngitis (week 52: 41% [2 mg kg-1 ], 47% [4 mg kg-1 ]) and AD exacerbation (29%, 42%). After one dupilumab dose in the phase IIa study, EASI improved from baseline to week 2 [mean ± SD reduction -34% ± 20% (2 mg kg-1 ) and -51% ± 29% (4 mg kg-1 )]. With continuing treatment, EASI scores improved further [week 52: -85% ± 12% (2 mg kg-1 ) and -84% ± 20% (4 mg kg-1 )].

Conclusions: In adolescents with moderate-to-severe AD, dupilumab's pharmacokinetic profile was similar to that in adults. These 52-week safety and efficacy data support long-term use of dupilumab in this patient population. What's already known about this topic? Adolescents with moderate-to-severe atopic dermatitis (AD) have high unmet medical need, with significant disease burden and limited treatment options. Dupilumab (monoclonal antibody against interleukin-4 receptor α) is approved for the treatment of adolescents with moderate-to-severe AD who are inadequately responsive to standard of care (U.S.A.) or candidates for systemic therapy (European Union). A 16-week, randomized, placebo-controlled phase III trial in adolescents demonstrated significant improvements in AD signs/symptoms with an acceptable safety profile. What does this study add? These studies demonstrate the long-term safety and efficacy of dupilumab in adolescents with moderate-to-severe AD for up to 52 weeks of treatment, thus extending and reinforcing the findings from the 16-week dupilumab phase III trial. The data from these studies also support the use of dupilumab in combination with current standard of care (topical corticosteroids), which was not evaluated in the 16-week phase III monotherapy trial.

Trial registration: ClinicalTrials.gov NCT03054428 NCT02407756.

© 2019 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

Figures

Figure 1
Figure 1
Mean log‐scaled concentrations of dupilumab in serum vs. nominal time. (a) Concentration–time profile of the phase IIa study. Vertical arrows represent time points at which dupilumab 2 mg kg−1 or 4 mg kg−1 was administered. (b) Concentration–time profile of the phase III open‐label extension (OLE). Patients in the OLE received dupilumab 2 mg kg−1 weekly or 4 mg kg−1 weekly. Linear‐scale concentration–time profiles and patient numbers are shown in Figure S4 (see Supporting Information). LLOQ, lower limit of concentration.
Figure 2
Figure 2
Efficacy end points. (a) Percentage change in Eczema Area and Severity Index (EASI) from baseline of the phase IIa study to week 52 of the phase III open‐label extension (OLE). (b) Proportion of patients achieving EASI‐50 (≥50% improvement from baseline) from the baseline of the phase IIa study to week 52 of the phase III OLE. (c) Proportion of patients achieving EASI‐75 (≥ 75% improvement from baseline in EASI) from the baseline of the phase IIa study to week 52 of the phase III OLE. (d) Proportion of patients achieving Investigator's Global Assessment (IGA) scores of 0 or 1 from the baseline of the phase IIa study to week 52 of the phase III OLE. (e) Percentage change in Peak Pruritus Numerical Rating Scale (NRS) from the baseline of the phase IIa study to week 52 of the phase III OLE. (f) Proportion of patients achieving a reduction of ≥ 3 points in Peak Pruritus NRS from the baseline of the phase IIa study to week 52 of the phase III OLE. (g) Percentage change in SCORing Atopic Dermatitis (SCORAD) from the baseline of the phase IIa study to week 52 of the phase III OLE.

References

    1. Eichenfield LF, Tom WL, Chamlin SL et al Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 2014; 70:338–51.
    1. Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. J Invest Dermatol 2011; 131:67–73.
    1. Odhiambo JA, Williams HC, Clayton TO et al; ISAAC Phase Three Study Group . Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol 2009; 124:1251–58.e23.
    1. Slattery MJ, Essex MJ, Paletz EM et al Depression, anxiety, and dermatologic quality of life in adolescents with atopic dermatitis. J Allergy Clin Immunol 2011; 128:668–71.
    1. Halvorsen JA, Lien L, Dalgard F et al Suicidal ideation, mental health problems, and social function in adolescents with eczema: a population‐based study. J Invest Dermatol 2014; 134:1847–54.
    1. Rhodes HL, Thomas P, Sporik R et al A birth cohort study of subjects at risk of atopy: twenty‐two‐year follow‐up of wheeze and atopic status. Am J Respir Crit Care Med 2002; 165:176–80.
    1. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003; 112(Suppl. 6):S118–27.
    1. Ekbäck M, Tedner M, Devenney I et al Severe eczema in infancy can predict asthma development: a prospective study to the age of 10 years. PLOS ONE 2014; 9:e99609.
    1. Schneider L, Hanifin J, Boguniewicz M et al Study of the atopic march: development of atopic comorbidities. Pediatr Dermatol 2016; 33:388–98.
    1. Burgess JA, Dharmage SC, Byrnes GB et al Childhood eczema and asthma incidence and persistence: a cohort study from childhood to middle age. J Allergy Clin Immunol 2008; 122:280–5.
    1. Wollenberg A, Barbarot S, Bieber T et al Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 2018; 32:657–82.
    1. Proudfoot LE, Powell AM, Ayis S et al The European TREatment of severe Atopic eczema in children Taskforce (TREAT) survey. Br J Dermatol 2013; 169:901–9.
    1. Totri CR, Eichenfield LF, Logan K et al Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: the PeDRA TREAT survey. J Am Acad Dermatol 2017; 76:281–5.
    1. Wollenberg A, Barbarot S, Bieber T et al Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018; 32:850–78.
    1. MacDonald LE, Karow M, Stevens S et al Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A 2014; 111:5147–52.
    1. Murphy AJ, Macdonald LE, Stevens S et al Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A 2014; 111:5153–8.
    1. Beck LA, Thaçi D, Hamilton JD et al Dupilumab treatment in adults with moderate‐to‐severe atopic dermatitis. N Engl J Med 2014; 371:130–9.
    1. Thaçi D, Simpson EL, Beck LA et al Efficacy and safety of dupilumab in adults with moderate‐to‐severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo‐controlled, dose‐ranging phase 2b trial. Lancet 2016; 387:40–52.
    1. Simpson EL, Bieber T, Guttman‐Yassky E et al Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375:2335–48.
    1. Blauvelt A, de Bruin‐Weller M, Gooderham M et al Long‐term management of moderate‐to‐severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1‐year, randomised, double‐blinded, placebo‐controlled, phase 3 trial. Lancet 2017; 389:2287–303.
    1. de Bruin‐Weller M, Thaçi D, Smith CH et al Dupilumab with concomitant topical corticosteroids in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol 2018; 178:1083–101.
    1. Wenzel S, Ford L, Pearlman D et al Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368:2455–66.
    1. Wenzel S, Castro M, Corren J et al Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium‐to‐high‐dose inhaled corticosteroids plus a long‐acting β2 agonist: a randomised double‐blind placebo‐controlled pivotal phase 2b dose‐ranging trial. Lancet 2016; 388:31–44.
    1. Bachert C, Mannent L, Naclerio RM et al Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA 2016; 315:469–79.
    1. Hirano I, Dellon ES, Hamilton JD et al Dupilumab efficacy and safety in adult patients with active eosinophilic esophagitis: a randomized double‐blind placebo‐controlled phase 2 trial. Presented at the World Congress of Gastroenterology at ACG 2017, Orlando FL, U.S.A., 13–18 October 2017.
    1. Castro M, Corren J, Pavord I et al Dupilumab efficacy and safety in moderate‐to‐severe uncontrolled asthma. N Engl J Med 2018; 378:2486–96.
    1. Rabe K, Nair P, Brusselle G et al Efficacy and safety of dupilumab in glucocorticoid‐dependent severe asthma. N Engl J Med 2018; 378:2475–85.
    1. Bachert C, Han JK, Desrosiers M et al Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS‐24 and LIBERTY NP SINUS‐52): results from two multicentre, randomised, double‐blind, placebo‐controlled, parallel‐group phase 3 trials. Lancet 2019; doi: 10.1016/S0140-6736(19)31881-1.
    1. DUPIXENT® (dupilumab). Highlights of prescribing information. Available at: (last accessed 3 September 2019).
    1. DUPIXENT® (dupilumab). Summary of product characteristics. Available from: (last accessed 3 September 2019).
    1. Kovalenko P, DiCioccio AT, Davis JD et al Exploratory population PK analysis of dupilumab, a fully human monoclonal antibody against IL‐4Rα in atopic dermatitis patients and normal volunteers. CPT Pharmacometrics Syst Pharmacol 2016; 5:617–24.
    1. Davis J, Rawal S, Paccaly A et al Pharmacokinetics of dupilumab in phase 3 confirmatory studies in adult patients with moderate‐to‐severe atopic dermatitis. Clin Pharmacol Ther 2017; 101(Suppl. 1):S61.
    1. Treister AD, Lio PA. Long‐term off‐label dupilumab in pediatric atopic dermatitis: a case series. Pediatr Dermatol 2019; 36:85–8.
    1. Siegfried EC, Igelman S, Jaworsk JC. Use of dupilimab in pediatric atopic dermatitis: access, dosing, and implications for managing severe atopic dermatitis. Pediatr Dermatol 2019; 36:172–6.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe